Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5285249
Max Phase: Preclinical
Molecular Formula: C19H20FNO3S
Molecular Weight: 361.44
Associated Items:
ID: ALA5285249
Max Phase: Preclinical
Molecular Formula: C19H20FNO3S
Molecular Weight: 361.44
Associated Items:
Canonical SMILES: C[C@H](C(=O)N[C@@H]1Cc2ccccc2[C@H]1S(C)(=O)=O)c1ccc(F)cc1
Standard InChI: InChI=1S/C19H20FNO3S/c1-12(13-7-9-15(20)10-8-13)19(22)21-17-11-14-5-3-4-6-16(14)18(17)25(2,23)24/h3-10,12,17-18H,11H2,1-2H3,(H,21,22)/t12-,17+,18+/m0/s1
Standard InChI Key: XLOBFEKJZJYISQ-JBBXEZCESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 361.44 | Molecular Weight (Monoisotopic): 361.1148 | AlogP: 2.76 | #Rotatable Bonds: 4 |
Polar Surface Area: 63.24 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 2.43 | CX LogD: 2.43 |
Aromatic Rings: 2 | Heavy Atoms: 25 | QED Weighted: 0.91 | Np Likeness Score: -0.68 |
1. Dickson L, Teall M, Chevalier E, Cheung T, Liwicki GM, Mack S, Stephenson A, White K, Fosbeary R, Harrison DC, Brice NL, Doyle K, Ciccocioppo R, Wu C, Almond S, Patel TR, Mitchell P, Barnes M, Ayscough AP, Dawson LA, Carlton M, Bürli RW.. (2023) Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist., 14 (4): [PMID:37077399] [10.1021/acsmedchemlett.2c00529] |
Source(1):